Overview of the Coming National Drug Code Format Change
Presented by Victoria Pankovich
May 20, 2026 | 1:00 PM ET
EAS Consulting Group is hosting a complimentary webinar, Overview of the Coming National Drug Code (NDC) Format Change.
The FDA has finalized a rule establishing a uniform 12-digit National Drug Code format, replacing the current 10-digit configurations. The new standardized format is intended to improve consistency and interoperability across the pharmaceutical supply chain.
The rule will take effect on March 7, 2033, at which point FDA will begin assigning only 12-digit NDCs and converting all existing 10-digit NDCs to the new format. A three-year transition period will follow, allowing companies time to update labeling and systems before full enforcement.
This change will impact manufacturers, repackagers, distributors, and other stakeholders responsible for drug listing and labeling.
Join EAS for a review of the Federal Register notice and a discussion of:
- The structure of the new 12-digit NDC format
- How existing NDCs will be converted
- Key timelines and transition expectations
- What the change means for regulatory and labeling functions
This webinar is designed for professionals responsible for regulatory affairs, labeling, and compliance within FDA-regulated organizations.
EAS Consulting Group can support organizations as they evaluate the impact of this change and plan for implementation.
Registration Coming Soon
About the Presenters
Victoria Pankovich
Manager, Regulatory Services
Reporting to the Senior Director Pharmaceutical & Medical Device Consulting, Victoria Pankovich supports clients through assembling and processing FDA submissions including Drug Master Files, Abbreviated New Drug Applications and New Drug Applications. Serve as the primary US Agent for all required communications with FDA on behalf of clients, including Establishment Inspection coordination with FDA, Drug, Medical Device and Food facilities registration; Drug and Medical Device product listings; Color Certification requests; FDA Inspection Notifications; FOl and FDA Controlled Correspondence requests.